[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-condition":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,79,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100549392","pause-sick-day-medication-management-mobile-app-study-100549392",false,"NCT06433414","PAUSE: Sick Day Medication Management Mobile App Study","Preventing Medication Complications During AcUte Illness Through Symptom Evaluation and Sick Day Guidance Mobile Application (PAUSE)","PAUSE","Inclusion Criteria:\n\n* ≥18 years of age and able to provide informed consent\n* be able to communicate (read, write, and speak) in English\n* have access to a smartphone\u002Ftablet with an Internet connection\n* be willing and able to download and use the PC Health app for the duration of the study\n* currently be taking 2 or more medications from the following classes: renin-angiotensin-aldosterone system (RAAS) antagonists, diuretics, oral NSAIDs, metformin, or 1 or more medications from the following classes: insulin, sulfonylureas, meglitinides, SGLT2 inhibitors.\n\nExclusion Criteria:\n\n* fail to meet the inclusion criteria\n* have kidney failure requiring maintenance dialysis\n* have had an organ transplant\n* are pregnant\n* receive qualifying medications in a blister pack or sachet\n* do not primarily manage their own medications and condition (i.e., receive home care, in a rehabilitation or medical respite facility)\n* cannot use the PC Health app independently\n* previously participated in studies that led to the development of the PAUSE App (including the PAUSE study usability testing or needs assessment focus groups)","ALL","18 Years","99 Years",{"count":21,"type":22},320,"ESTIMATED","INTERVENTIONAL",[25],"NA","Diabetes, heart disease and kidney disease have high morbidity and costs of care. Medications used to treat these conditions are effective. Yet, some have the risk of preventable adverse events when people are sick with the flu or stomach bug. These events include low blood sugar and acute kidney injury which can lead to extended hospital stays or death. Sick day medication guidance (SDMG) recommends stopping these medications temporarily when sick and restarted after symptoms subside. Unfortunately, many patients are not aware of these recommendations or find them hard to follow.\n\nThe investigator's previous research has shown that there is a lack of SDMG education and patient resources. Research on the development, implementation, usability and efficacy of these resources is also limited. In developing a SDMG tool, the investigators surveyed patients who expressed interest in an electronic health (eHealth) tool. As a result, the PAUSE App provides a timely and innovative way to provide continuity of care to patients that is linked to each patients' unique pharmacy record.\n\nIn the present pilot randomized control trial, the investigators will examine the outcomes of the PAUSE Initiative consisting of the PAUSE App and a SDMG educational handout. Approximately 16 Loblaw\u002FShoppers Drug Mart pharmacies across Alberta will take part. Patients of these pharmacies who take high-risk medications will be invited to participate. Each pharmacy will be randomized to provide their patients usual care (i.e. SDMG handout) or the intervention (i.e., PAUSE App + handout). Approximately 320 participants (20 per pharmacy) are expected to be recruited. The expected trial length is 9 months from recruitment to analysis.\n\nA simulated 'sick day' survey will be used to assess the fidelity and efficacy of the PAUSE Initiative. Feasibility of the study processes (i.e., recruitment, onboarding) will be assessed to inform a full-scale trial. The usability and acceptability of the PAUSE App will also be investigated. Pharmacists and participants will complete questionnaires and qualitative interviews to assess these outcomes. Additionally, PAUSE App user metrics will be collected. All participants will receive an honorarium for their time.",[28,29],"Chronic Condition","Adverse Event",[31,32,33],"chronic condition","medication safety","sick day medication guidance","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":22},"2027-01-01",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"University of Alberta","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100560835","digital-solution-for-salutogenic-brain-health-disab-a-pilot-protocol-for-clinical-implementation-100560835","NCT06582316","Digital Solution for Salutogenic Brain Health (DiSaB): A Pilot Protocol for Clinical Implementation","Digital Solution for Salutogenic Brain Health (DiSaB): A Pilot Sequential Multiple Assignment Randomised Trial (SMART) Protocol for Clinical Implementation","DiSaB","Inclusion Criteria:\n\n* Aged 40 - 55 years old\n* Have hypertension, hyperlipidaemia and\u002For type-2 diabetes\n* Ability to provide written informed consent\n* Posses sufficient English language skills in reading, writing and speaking\n* Multimorbidity conditions are also acceptable with the exception of life-threatening co-morbidities with life expectancy of less than one year\n* Total Risk Score (TRS) for cognitive impairment of at least 3\n\nExclusion Criteria:\n\n* Physical, visual and\u002For hearing impairment\n* Language impairment (i.e. severe dysarthria or aphasia)\n* Not within age range listed\n* Major or active psychiatric conditions\n* Diagnosis of dementia\n* Do not own a mobile device capable of downloading applications (i.e. Zoom), and\u002For do not have access to internet connection","40 Years","64 Years",{"count":57,"type":22},160,[25],"The goal of this clinical trial is to develop and learn if a digitally delivered brain health intervention (DiSaB) can help improve cognitive, physical and psychosocial health in middle-aged adults with chronic conditions at-risk for cognitive decline. The clinical trial also aims to find out the push and pull factors of implementing the intervention in primary care settings. The main questions it aims to answer are:\n\n1. Does the DiSaB intervention improve participants' cognitive functions, health measures, and psychosocial health?\n2. Is an individualised or group-based health education session better at improving cognitive, physical and psychosocial health in participants who did not respond to the DiSaB intervention?\n3. How useful and practical is the DiSaB intervention, according to\n\n   1. participants and\n   2. nurses carrying out the intervention?\n\nThe investigators will compare a DiSaB intervention to a control condition (where participants do not undergo any intervention) to see if the DiSaB intervention works in improving participants' health.\n\nThe investigators will also compare individualised versus group health education sessions to see which session is better at improving the health of participants who did not respond to the DiSaB intervention.\n\nParticipants will\n\n1. Complete cognitive assessments, questionnaires, and health tests before intervention, immediately after the intervention, and 6 months after the intervention\n2. Either undergo no intervention, or undergo the DiSaB intervention over 2 months\n3. Be randomly selected to attend focus group interviews\n\nLocal champions will complete questionnaires and attend focus group interviews after administering and\u002For co-facilitating the intervention.",[28],[62,63,64,65,66,67],"Cognition","Implementation Science","Digital Intervention","Hypertension","Hyperlipidaemia","Type-2 Diabetes","RECRUITING","2025-05-19",{"date":71,"type":38},"2025-05-22",{"date":73,"type":38},"2025-04-02",{"date":75,"type":22},"2026-06",{"name":77,"class":45},"National University of Singapore",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100521528","river-at-home-ketamine-protocols-100521528","NCT06070766","RIVER At Home Ketamine Protocols","Can Digital Health Technology Guide Medical Providers, in Treating Chronic Conditions With RIVER Ketamine Protocols Safely at Home?","Inclusion Criteria:\n\nMust have an identifiable chronic condition.\n\nExclusion Criteria:\n\nHealthy Population",{"count":87,"type":22},50000,"OBSERVATIONAL","Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing and improving even one risk area will reverberate and improve other areas and the quality of life.\n\nRIVER Foundation is completing a 500-participant pilot study researching the safety of oral and nasal ketamine at home with no therapy. The pilot study examined three psychological scales: P.H.Q. 9, G.A.D. 7, and PCL5 scores. The interim report will be available in Nov 2023 with a final report in June 2024.\n\nThe lack of knowledge for the average medical practitioner makes ketamine a boutique medicine, often costly and unaffordable to those in need. Yet daily medical providers are eliminating ketamine as a choice in the treatment of chronic conditions.\n\nThe pilot study demonstrated the who, and where. The who, was adults with a chronic condition. The pilot study demonstrated the majority of those who could use ketamine are not receiving it due to cost. According to the 500-participant study, ketamine is safe and effective for at-home use thus demonstrating the where (at home with no supervision).",[28,91,92,93,94,95],"Chronic Pain","Chronic Disease","Major Depressive Disorder","Post Traumatic Stress Disorder","Anxiety Disorders",[97,98,99],"Ketamine","Neuroinflammation","Auricular","2024-11-22",{"date":102,"type":38},"2024-11-26",{"date":104,"type":38},"2023-10-01",{"date":106,"type":22},"2029-04-01",{"name":108,"class":45},"RIVER Foundation",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100559012","feasibility-and-potential-impact-of-an-individualized-exercise-program-via-a-telerehabilitation-device-in-chronic-patients-a-pilot-study-100559012","NCT06558591","Feasibility and Potential Impact of an Individualized Exercise Program Via a Telerehabilitation Device in Chronic Patients: A Pilot Study","Inclusion Criteria for professionals of exercise rehabilitation (ER):\n\n* Be a physiotherapist or kinesiologist working in the public sector, private sector, or in a mixed capacity,\n* Have been graduated for at least one year,\n* Conduct ER program with chronic patients and provide written consent.\n\nInclusion Criteria for chronic patients :\n\n* Be 18 years of age or older,\n* Be able to walk with or without assistives devices\n* Be capable of giving informed consent,\n* Be registered with the French health social security system,\n* Be under the care of a rehabilitation exercise professional.\n\nNon-inclusion criteria for patients :\n\n* Have an intolerance or inability to use digital tools,\n* Have a cognitive impairment,\n* Have contraindications to physical activity (unstable diabetes, unstable hypertension, unstable angina, intracardiac thrombus).",{"count":117,"type":22},50,[25],"Exercise Rehabilitation (ER) is widely used and effective in the treatment of chronic diseases; however, patients do not adhere to ER programs. Tele-rehabilitation is effective and often used to support and improve patient adherence. Thus, the ADEPINA device could be a promising solution for the individualized management of patients by their therapists. The aim of the study will be: a) To assess functional improvement, measured by the 6-minute walk test (6MWT) after the 12 weeks ER program in people with chronic disease. Additionally, the study will assess the individualized program' adherence and his effect on patients' physical fitness and quality of life. Methods: Fifty patients will follow individualized ER sessions to their patients (with chronic diseases) using the ADEPINA device, 2 to 3 times per week for 12 weeks. At the end of the intervention, the investigator will assess patients' lower limb strength (with sit to stand test), dynamic balance (Timed up and go test), patients' adherence to the ER program by evaluating the usage time of the system by participants, the treatment credibility and participant expectations for improvement will be assessed with the French version of the Credibility and Expectancy Questionnaire. The investigator will also evaluate the patients' quality of life (using the \"World Health Organization Quality of Life\" (WHOQOL) scale) at the beginning and end of the intervention. Discussion: This interventional pilot study could have positive impacts for participants and explore gaps in the current literature regarding the individualized telerehabilitation program' feasibility.",[92,28,121,122,123],"Stroke Sequelae","Age Problem","Parkinson Disease",[125,126,127,128,129],"Physical training","Telerehabilitation","Fitness test","health professional","chronic disease","2024-08-14",{"date":132,"type":38},"2024-08-16",{"date":134,"type":22},"2025-01",{"date":136,"type":22},"2027-07",{"name":138,"class":45},"Limoges University"]